文献速递银屑病与炎症性皮肤病

阿普斯特治疗中重度斑块状银屑病的真实世界疗效与安全性数据

Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-03-30

本研究在门诊分析了首批51例接受阿普斯特治疗的中重度斑块状银屑病患者,主要终点为16周时PASI下降百分比。持续用药者中59.3%达到至少ΔPASI75,11.1%达到50%≤PASI<75%且DLQI≤5,5例(18.5%)达到ΔPASI100;28%停药,早期多因不良事件(12%),后期多因疗效不足(16%)。作者认为阿普斯特安全有效。

要点

  • 持续用药者16周时59.3%达到至少ΔPASI75,5例(18.5%)达到ΔPASI100。
  • 11.1%达到50%≤PASI<75%且DLQI≤5的满意应答以维持治疗。
  • 28%停药,早期多因不良事件(12%,以胃肠道症状最常见),后期多因疗效不足(16%)。

核心结论

  • 阿普斯特是银屑病患者安全有效的治疗选择,16周内70.4%的患者达到ΔPASI75和ΔPASI50应答并伴DLQI≤5。
  • 这些来自真实世界的结果印证了大型III期临床试验中已证明的阿普斯特疗效和安全性。

研究设计与样本

  • 本研究在研究者所在门诊分析了首批51例接受阿普斯特治疗的中重度斑块状银屑病患者。
  • 主要终点为治疗开始后16周时根据PASI下降百分比(ΔPASI)评估的临床应答。
  • 次要终点包括第16周时的PASI、DLQI、PGA、PSSI、达到ΔPASI50/75/90/100的患者百分比、不良事件、停药原因及药物生存率。

主要发现

  • 持续使用阿普斯特的患者中59.3%在第16周达到至少ΔPASI75,11.1%达到50%≤PASI<75%且DLQI≤5的满意应答。
  • 5例患者(18.5%)达到ΔPASI100。
  • 28%的患者停用阿普斯特,多数在前4周因不良事件(12%)停药,胃肠道症状最常见;后期因疗效不足(16%)停药。
  • 与治疗前测量值相比,治疗4周和16周后PASI、DLQI、PGA和PSSI评分均观察到统计学显著改善。

关键数值与推荐

  • 持续用药者第16周达到至少ΔPASI75者为59.3%。
  • 达到50%≤PASI<75%且DLQI≤5者为11.1%。
  • 达到ΔPASI100者为5例(18.5%)。
  • 停药者占28%,其中前4周因不良事件停药者占12%,后期因疗效不足停药者占16%。
  • 16周内达到ΔPASI75和ΔPASI50应答并伴DLQI≤5的患者占70.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, which requires long-term, safe and effective treatment. Apremilast, a small-molecule PDE4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015. OBJECTIVE: We analysed and report the efficacy and safety of apremilast in the first 51 patients with psoriasis that have undergone treatment with this novel small molecule in our outpatient clinic. METHOD: Our primary endpoint was the evaluation of clinical response to apremilast according to the percentage of Psoriasis Area Severity Index (PASI) reduction (ΔPASI) at 16 weeks after treatment initiation. Secondary endpoints were the evaluation at week 16 of (i) PASI; (ii) Dermatology Life Quality Index (DLQI); (iii) Physician Global Assessment (PGA); (iv) Psoriasis Scalp Severity Index (PSSI); and (v) the percentage of patients who achieved ΔPASI50, ΔPASI75, ΔPASI90 and ΔPASI100; (vi) adverse events (AE); (vii) reasons for drug discontinuation; and (viii) drug survival. RESULTS: About 59.3% of the patients who remained on apremilast achieved at least ΔPASI75 at week 16, while 11.1% achieved combined 50% ≤ PASI < 75% and DLQI ≤ 5 (satisfactory response) adequate enough to maintain treatment. Five patients (18.5%) also achieved ΔPASI100. Patients discontinued apremilast (28%), mostly during the first 4 weeks due to adverse events (12%) with gastrointestinal symptoms being the most common, and later due to lack of efficacy (16%). A statistically significant improvement of PASI, DLQI, PGA and PSSI scores was observed after 4 and 16 weeks of treatment relative to pretreatment measurements. CONCLUSION: Apremilast is a safe and efficacious treatment for psoriasis patients as it produces ΔPASI75 and ΔPASI50 responses combined with DLQI ≤ 5 in 16 weeks in 70.4% of the patients. These results, from a real-world setting, confirm the efficacy and safety of apremilast which has been demonstrated in large phase III clinical trials.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Papadavid E, Rompoti N, Theodoropoulos K, et al. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018. PMID: 29388335. doi:10.1111/jdv.14832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。